Genfit SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0004163111
EUR
8.31
-0.19 (-2.18%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

  • ROCE(HY) Lowest at -52.12%
  • PRE-TAX PROFIT(Q) At EUR -12.13 MM has Fallen at -142.96%
  • NET PROFIT(Q) At EUR -9.96 MM has Fallen at -132.85%
2

With ROE of -74.43%, it has a Very Expensive valuation with a 8.36 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 422 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.54

stock-summary
Return on Equity

-74.43%

stock-summary
Price to Book

8.10

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
61.46%
0%
61.46%
6 Months
165.65%
0%
165.65%
1 Year
148.21%
0%
148.21%
2 Years
150.45%
0%
150.45%
3 Years
129.57%
0%
129.57%
4 Years
134.75%
0%
134.75%
5 Years
106.64%
0%
106.64%

Genfit SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
6.05%
EBIT Growth (5y)
8.67%
EBIT to Interest (avg)
-3.09
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.27
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
5.82%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.36
EV to EBIT
-14.77
EV to EBITDA
-15.69
EV to Capital Employed
5.79
EV to Sales
11.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-39.22%
ROE (Latest)
-74.43%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Genfit SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 134.27% vs 41.58% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 105.19% vs -21.94% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "67.00",
          "val2": "28.60",
          "chgp": "134.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.40",
          "val2": "-34.90",
          "chgp": "104.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.80",
          "val2": "4.60",
          "chgp": "4.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.50",
          "val2": "-28.90",
          "chgp": "105.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5.20%",
          "val2": "-1,279.70%",
          "chgp": "127.45%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
67.00
28.60
134.27%
Operating Profit (PBDIT) excl Other Income
1.40
-34.90
104.01%
Interest
4.80
4.60
4.35%
Exceptional Items
0.00
0.50
-100.00%
Consolidate Net Profit
1.50
-28.90
105.19%
Operating Profit Margin (Excl OI)
-5.20%
-1,279.70%
127.45%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 134.27% vs 41.58% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 105.19% vs -21.94% in Dec 2023

stock-summaryCompany CV
About Genfit SA stock-summary
stock-summary
Genfit SA
Pharmaceuticals & Biotechnology
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Company Coordinates stock-summary
Company Details
Parc Eurasante 885 avenue Eugene Avinee , LOOS None : 59120
stock-summary
Tel: 33 3 20164000
stock-summary
Registrar Details